CompletedNot Applicable

Developmental Dyslexia and Remediation Methods

France145 participantsStarted 2019-10-25

Plain-language summary

At least, three theoretical frameworks are currently involved in therapeutic research in developmental dyslexia. Each theoretical framework relies on the type of underlying cognitive processes that is viewed as impaired: 1°) phonological processing, 2°) cross modal integration, 3°) visual attention processing. In this controlled and randomized study, three types of computerized training are combined in a multi-factorial remedial approach in 8 to 12 year old children with dyslexia. The main objective is to compare the effectiveness of this remedial approach which combines phonological, visual-attentional and cross-modal training with conventional non-intensive and non-specific rehabilitation

Who can participate

Age range8 Years – 13 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 8 years old and ≤ at 13 years old; * Diagnosis of dyslexia validated by performances ≤ at -1.5 standard deviations from the mean on leximetric tests. * Diagnosis of mixed dyslexia validated by performances ≤ at -1.5 standard deviations from the mean for reading irregular words and pseudo-words in the Evalec© test. * Performance ≤ at -1.5 standard deviations from the mean for phonological (Evalec©) and visual-attentional tasks in the Evadys© and Sigl© tests. * Home equipped with a connected computer system for daily training. * Signing of informed consent by the parents * The child must be affiliated to a social security scheme Exclusion Criteria: * Intellectual retardation, neurological disorders, pervasive developmental disorder; * Primary sensory deficit; * Educational deficiencies; * attention deficit hyperactivity disorder, dysphasia; * Previous daily phonological or visual-attentional training.

What they're measuring

reading skills effectiveness

Timeframe: 26 weeks to baseline

Trial details

NCT IDNCT04028310

SponsorFondation Lenval

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-12